HUYA Bioscience International Celebrates 10 Years in China

« Return

Biopharma Company with Joint HQ in Shanghai & San Diego Commemorates a Decade of Innovation

Shanghai, China – March 22, 2016HUYA Bioscience International (HUYA) celebrated the 10th anniversary of the opening of its first offices in China with a gala dinner at the ‘M on the Bund’ restaurant in Puxi, Shanghai. Executives commemorated a decade of leadership in enabling and accelerating the global development of novel biopharmaceutical product opportunities originating in China.

Original jpeg photo 10th year anniversary
(From left – Dr. Bob Goodenow, HUYA’s Chief Business Officer; Mr. Fangda Hua, Secretary General of Shanghai Cancer Rehabilitation Club; Dr. Mireille Gillings, HUYA’s Founder and Executive Chair; Mr. Clement Gingras, HUYA’s CTO & COO Asia.)


Today, HUYA has offices in eight strategic locations across China (Shanghai, Beijing, Chengdu, China Medical City in Taizhou, Guangzhou, Hangzhou, Shenzhen and Wuhan), as well as in Tokyo, Japan; Seoul, South Korea; and San Diego, California, USA. Over the last decade, the company has established more than 110 agreements with Chinese universities, research institutes and hi-tech science parks and built the world’s largest database of China-sourced compounds, including over 14,000 China-sourced compounds across multiple therapeutic areas. HUYA has also made unprecedented use of the Tripartite Cooperation Treaty between China, Japan and South Korea to advance development of the company’s lead drug HBI-8000 in Japan for lymphoma. HBI-8000 is the first approved oral class I-selective histone deacetylase (HDAC) inhibitor with immuno-oncology properties.

“Congratulations to the entire HUYA team on this milestone, and warmest thanks for your dedication over the years,” said Dr. Mireille Gillings, HUYA’s founder, CEO & Executive Chair. “Here’s to the next 10 years – may they be even more successful!”

As part of the HUYA team’s mission to develop new treatments for cancer and bring benefits to cancer patients, the company announced that they have donated 80,000 RMB to the Shanghai Cancer Rehabilitation Club, a non-governmental self-help mutual aid organization that provides psychological support, physical training, and rehabilitation courses to cancer patients. Representatives from the Shanghai Cancer Rehabilitation Club were in attendance at the HUYA gala event, where they received the donation and shared their experiences with the guests at the event.

The 10-year celebration coincides with several landmark events for HUYA.  In February 2016, the Company executed a major agreement with Eisai Co. Ltd, for exclusive rights to HUYA’s lead drug, HBI-8000, in Japan, South Korea, Thailand, Malaysia, Indonesia, Philippines, Vietnam and Singapore. HUYA will receive $280M in upfront and milestone payments plus royalties on net sales. The deal stemmed from HUYA’s efforts and vision of leveraging clinical data generated within Asia, using the Tripartite Cooperation Treaty between China, Japan and South Korea to expand into other countries such as Japan and South Korea.  In an unprecedented move, HUYA also recently received orphan drug designation for HBI-8000 in Japan for peripheral T-cell lymphoma (PTCL).  HUYA  advanced HBI-8000 from an approval for lymphoma in China to a registration path in Japan under an Orphan Drug Designation, complementing HUYA’s development in the United States and expansion into immuno-oncology (IO). Most recently, HUYA acquired worldwide ex-China rights from Fudan University for a platform of compounds that builds upon HUYA’s IO franchise and continues the vision of globalizing innovation from China.

About HUYA Bioscience International

HUYA Bioscience International is the leader in enabling and accelerating the global development of novel biopharmaceutical product opportunities originating in China. Extensive collaborations are established with Chinese biopharmaceutical, academic and commercial organizations to speed development and value creation in worldwide markets for China-sourced product candidates. With the largest Chinese compound portfolio covering all therapeutic areas, HUYA has emerged as the partner-of-choice for maximizing the value of biopharmaceutical innovation in China. HUYA has offices in the U.S., Japan, South Korea and eight strategic locations across China. With the largest team of scientists working with Chinese innovators, HUYA identifies and advances promising drug candidates globally. HUYA received an Asia-Pacific Stevie® Award in the Health Products and Services & Pharmaceuticals category, and Dr. Mireille Gillings received the Gold Stevie Award in the Woman of the Year 2015 American Business Award category. For more information, please visit .

Contact Details:

Yiota Merianos
HUYA Corporate Communications
+1 858 353 1217